Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump
Helus Pharma reported that its psychedelic drug, HLP003, showed significant improvement in depression symptoms in a late-stage trial. The drug, a modified version of psilocin, is designed to be used with standard antidepressants. The company's shares rose over 20% in premarket trading. According to Helus, 56.3% of patients treated with HLP003 saw their symptoms cut by at least half, compared with 28.2% on placebo.
How this was made

The 30-second read
Why it matters
The trial data provides the first robust efficacy signal, likely prompting short‑term price appreciation and increased analyst coverage.
Market read
Immediate share rally; sector may benefit from renewed interest in psychedelic therapeutics.
What to watch
Potential competition from other psychedelics and the need for larger Phase 3 data.
Background
Helus Pharma is a small‑cap biotech focused on psychedelic treatments for depression.
Market effects
Boosts sentiment for the emerging psychedelic‑therapy sector and may lift peers.
U.S. biotech stocks could see modest gains.
Limited to biotech investors; no broad market effect.
Counterpoint
Skeptics may question long‑term safety and regulatory path, suggesting caution.
Key entities
- companyHelus Pharma
U.S.-listed biotech developing HLP003.
- drugHLP003
Modified psilocin candidate for major depressive disorder.




